<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03945071</url>
  </required_header>
  <id_info>
    <org_study_id>IRB 9810</org_study_id>
    <nct_id>NCT03945071</nct_id>
  </id_info>
  <brief_title>The Effect of Punctal Plugs on Ocular Surface After Povidone-Iodine Preparation of Intravitreal Injection</brief_title>
  <official_title>The Effect of Punctal Plugs in Reducing Ocular Surface Irritation After Povidone-Iodine Preparation of Intravitreal Injection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oklahoma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the effectiveness of punctal plugs in reducing ocular
      surface (eye surface) irritation after intravitreal injections prepared by povidone-iodine 5%
      solution.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intravitreal injection is a shot of medication into the eye. Many retinal diseases, such as
      diabetic retinopathy, neovascular age-related macular degeneration, and retinal vein
      occlusions require regular, periodic injections. Patients often reports eye surface
      irritation post intravitreal injection. One of the reasons for such discomfort is attributed
      to povidone-iodine solution used to clean the eye surface to reduce sight-threatening
      infections. Patients who already experience symptoms of dry eye are at increased risk of
      discomfort after povidone-iodine prepped intravitreal injections.

      Povidone-iodine is known to be corrosive to the corneal epithelium and delay eye surface
      healing. Human tears contain proteins and chemicals that lubricate, heal, and protect the eye
      surface from infections and irritants. Adequate tear film therefore not only dilutes
      povidone-iodine, but also promotes corneal healing post povidone-iodine prepping.

      The primary long-term objective of the present study is to investigate whether punctal plugs
      will reduce eye discomfort post intravitreal injections as reported by the Ocular Surface
      Disease Index (OSDI) and other relevant surveys. The secondary outcome is to describe any
      other risk and protective factors associated with eye surface discomfort after intravitreal
      injections.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2019</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in ocular (eye) discomfort</measure>
    <time_frame>From date of randomization until date of death from any cause, whichever came first, assessed up to 100 weeks</time_frame>
    <description>Measure participants' level of discomfort after punctal plugs using the Ocular Surface Disease Index (OSDI), which is a paper survey that participants fill out based on their symptoms and level of ocular discomfort (if any).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Dry Eye Syndromes</condition>
  <condition>Dry Eye</condition>
  <condition>Ocular Surface Disease</condition>
  <arm_group>
    <arm_group_label>Puntal plug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive temporary punctal plug after intravitreal injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Punctual plug</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects will not receive temporary punctal plug after intravitreal injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Punctal plug</intervention_name>
    <description>Punctal plug will be given to subjects after intravitreal injection in half of the study subjects</description>
    <arm_group_label>Puntal plug</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of age-related macula degeneration

          -  Clinical diagnosis of diabetic retinopathy

          -  Clinical diagnosis of retinal vein occlusion

        Exclusion Criteria:

          -  Currently wearing punctal plugs

          -  History of punctal cautery,

          -  Active ocular infection

          -  History of ocular infection

          -  Eyelid trauma

          -  Eyelid surgery

          -  Graft versus host disease

          -  Thyroid eye disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Douglas Jin, M.D.</last_name>
    <phone>405-271-6060</phone>
    <email>Douglas-Jin@DMEI.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vinay Shah, M.D.</last_name>
    <phone>405-271-6060</phone>
    <email>Vinay-Shah@dmei.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dean McGee Eye Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Douglas Jin, M.D.</last_name>
      <phone>405-271-6060</phone>
      <email>Douglas-Jin@dmei.org</email>
    </contact>
    <contact_backup>
      <last_name>Daniel B Carrel</last_name>
      <phone>405-271-6060</phone>
      <email>Daniel-Carrel@dmei.org</email>
    </contact_backup>
    <investigator>
      <last_name>Douglas Jin, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vinay Shah, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Goldberg RA. How to prevent endophthalmitis after intravitreal injections. Int J Retina Vitreous. 2015 Aug 11;1:12. eCollection 2015.</citation>
    <PMID>27847605</PMID>
  </reference>
  <reference>
    <citation>Laude A, Lim JW, Srinagesh V, Tong L. The effect of intravitreal injections on dry eye, and proposed management strategies. Clin Ophthalmol. 2017 Aug 16;11:1491-1497. doi: 10.2147/OPTH.S136500. eCollection 2017. Review.</citation>
    <PMID>28860698</PMID>
  </reference>
  <reference>
    <citation>Marcet MM, Shtein RM, Bradley EA, Deng SX, Meyer DR, Bilyk JR, Yen MT, Lee WB, Mawn LA. Safety and Efficacy of Lacrimal Drainage System Plugs for Dry Eye Syndrome: A Report by the American Academy of Ophthalmology. Ophthalmology. 2015 Aug;122(8):1681-7. doi: 10.1016/j.ophtha.2015.04.034. Epub 2015 May 30. Review.</citation>
    <PMID>26038339</PMID>
  </reference>
  <reference>
    <citation>Ridder WH 3rd, Oquindo C, Dhamdhere K, Burke J. Effect of Povidone Iodine 5% on the Cornea, Vision, and Subjective Comfort. Optom Vis Sci. 2017 Jul;94(7):732-741. doi: 10.1097/OPX.0000000000001091.</citation>
    <PMID>28609415</PMID>
  </reference>
  <reference>
    <citation>Saedon H, Nosek J, Phillips J, Narendran N, Yang YC. Ocular surface effects of repeated application of povidone iodine in patients receiving frequent intravitreal injections. Cutan Ocul Toxicol. 2017 Dec;36(4):343-346. doi: 10.1080/15569527.2017.1291665. Epub 2017 Feb 28.</citation>
    <PMID>28166657</PMID>
  </reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>February 10, 2019</study_first_submitted>
  <study_first_submitted_qc>May 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2019</study_first_posted>
  <last_update_submitted>May 7, 2019</last_update_submitted>
  <last_update_submitted_qc>May 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

